Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

Yale University Cancer Center

New Haven, Connecticut

Daniel P. Petrylak, MD, is currently Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut. He is a recognized international leader in the urology field. He earned his MD at Case Western Reserve University School of Medicine in Cleveland Ohio. He then went on to complete his Internal Medicine Residency at Albert Einstein College of Medicine/Jacobi Medical Center in the Bronx, and his fellowship at Memorial Sloan Kettering Cancer Center in New York. Dr. Petrylak has served as principal investigator (PI) or co-PI on several SWOG clinical trials for genitourinary cancers. Most notably, he served as the PI for a randomized trial that led to the FDA approval of docetaxel in hormone refractory prostate cancer. He also helped to design and served as PI for the SPARC trial, an international registration trial evaluating satraplatin as a second-line therapy for hormone refractory prostate cancer. Dr. Petrylak served on the program committees for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a committee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, and Clinical Cancer Research.

Articles by Daniel P. Petrylak, MD

Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma

Daniel P. Petrylak, MD, discusses the recent FDA approval of the antibody drug complex enfortumab vedotin for treating refractory advanced urothelial disease in patients previously treated with immunotherapy and chemotherapy. He describes how the drug complex works to fight bladder cancer by recognizing Nectin-4, a biomarker expressed on the surface of bladder cancer cells, and delivering MMAE to cause cytotoxic activity. Dr. Petrylak further describes the design, execution, and results of the clinical trial that led to the drug’s approval, as well as notable side effects.

Read More

FDA Approves Pembrolizumab for New Indication of NMIBC

Daniel P. Petrylak, MD, discusses the recent FDA approval of the checkpoint inhibitor pembrolizumab for treating cystectomy-ineligible (or those who have refused cystectomy) non-muscle invasive bladder cancer patients who have also failed BCG. He details the prior lack of available treatment for this disease, explains the function of the drug as a checkpoint inhibitor, and describes the study that led to the drug’s approval.

Read More

ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers

E. David Crawford, MD, interviews Daniel P. Petrylak, MD, about a Phase 1b trial of cisplatin-ineligible bladder cancer patients given a combination of pembrolizumab and enfortumab vedotin that resulted in a 71% response rate. Dr. Petrylak details what makes a patient cisplatin-ineligible, discusses the partial and complete responses to the drug combination, and lays out future plans to study the efficacy of this therapy in the treatment of urothelial cancer.

Read More

Immunotherapy for Castrate-Resistant Prostate Cancer

Daniel P. Petrylak, MD, analyzes the current status of immunotherapy for prostate cancer, reviewing available options, emerging combination therapies, and immunotherapy clinical trials. He also emphasizes the impact of PD-L1 expression, microsatellite instability, and other mutations in prostate cancer on patient responses to immunotherapy. 

Read More

Join the GRU Community

- Why Join? -